Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.

MLA

Li, Aidan C., et al. “Quantitative Digital Imaging Analysis of HER2 Immunohistochemistry Predicts the Response to Anti-HER2 Neoadjuvant Chemotherapy in HER2-Positive Breast Carcinoma.” Breast Cancer Research & Treatment, vol. 180, no. 2, Apr. 2020, pp. 321–29. EBSCOhost, https://doi.org/10.1007/s10549-020-05546-0.

APA

Li, A. C., Zhao, J., Zhao, C., Ma, Z., Hartage, R., Zhang, Y., Li, X., & Parwani, A. V. (2020). Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Research & Treatment, 180(2), 321–329. https://doi.org/10.1007/s10549-020-05546-0

Chicago

Li, Aidan C., Jing Zhao, Chao Zhao, Zhongliang Ma, Ramon Hartage, Yunxiang Zhang, Xiaoxian Li, and Anil V. Parwani. 2020. “Quantitative Digital Imaging Analysis of HER2 Immunohistochemistry Predicts the Response to Anti-HER2 Neoadjuvant Chemotherapy in HER2-Positive Breast Carcinoma.” Breast Cancer Research & Treatment 180 (2): 321–29. doi:10.1007/s10549-020-05546-0.